IOL Chemicals Profit Jumps 36% to ₹137.64 Cr in FY26 on Strong Revenue Growth

HEALTHCAREBIOTECH
Whalesbook Corporate News Logo
AuthorIshaan Verma|Published at:
IOL Chemicals Profit Jumps 36% to ₹137.64 Cr in FY26 on Strong Revenue Growth
Overview

IOL Chemicals & Pharmaceuticals announced a strong financial year for FY26, with its consolidated profit soaring 36.18% to ₹137.64 crore on revenue growth of 11.36%. The company is funding its expansion plans, including new product lines, using its own capital.

Instant Stock Alerts on WhatsApp

Used by 10,000+ active investors

1

Add Stocks

Select the stocks you want to track in real time.

2

Get Alerts on WhatsApp

Receive instant updates directly to WhatsApp.

  • ✓Quarterly Results
  • ✓Concall Announcements
  • ✓New Orders & Big Deals
  • ✓Capex Announcements
  • ✓Bulk Deals
  • ✦And much more
Add StocksGet it on Google PlayDownload on the App Store

IOL Chemicals Reports Strong FY26 Results, Profit Up 36%

IOL Chemicals & Pharmaceuticals Ltd. has reported impressive financial results for the fiscal year 2025-26. The company posted a consolidated profit of ₹137.64 crore, marking a significant 36.18% increase from the previous year's ₹101.07 crore. Consolidated revenue also saw healthy growth, rising 11.36% to ₹2,340.44 crore from ₹2,101.62 crore.

Fourth Quarter Performance

The company's fourth quarter of FY26 showed robust year-on-year growth. Profit for the quarter surged by 69.19% to ₹53.16 crore, supported by a 16.72% increase in revenue, which reached ₹621.29 crore.

Growth Drivers and Financial Strength

This performance highlights IOL Chemicals' operational efficiency and strong market demand. The substantial profit increase reflects improved margins and effective cost management. Notably, the company is financing its expansion projects, such as the new "Triacetin" plant and increased "Pantoprazole" capacity, through internal funds, demonstrating financial stability and sound capital strategy.

Financial Highlights

  • FY26 Consolidated Revenue: ₹2,340.44 crore (Up 11.36% year-over-year)
  • FY26 Consolidated Profit: ₹137.64 crore (Up 36.18% year-over-year)
  • Q4 FY26 Consolidated Revenue: ₹621.29 crore (Up 16.72% year-over-year)
  • Q4 FY26 Consolidated Profit: ₹53.16 crore (Up 69.19% year-over-year)
  • Basic and Diluted EPS (FY26): ₹4.69

Key Considerations

A one-time exceptional charge of ₹11.21 crore impacted the year's profit. This charge was related to restructured employee compensation following new Labour Code notifications. The company's current borrowings saw a slight increase to ₹132.00 crore from ₹117.04 crore. Additionally, IOL Life Sciences Limited, a subsidiary, was officially struck off the company register effective April 1, 2026.

What to Watch Next

Investors will be keen to see how the new "Triacetin" plant and the expanded "Pantoprazole" capacity contribute to future revenues. Monitoring the impact of the exceptional item and any changes in borrowing levels will also be important.

Get stock alerts instantly on WhatsApp

Quarterly results, bulk deals, concall updates and major announcements delivered in real time.

Add Stocks
Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.